Skip to main content
. 2015 Nov 23;34(10):1034–1042. doi: 10.1200/JCO.2015.62.1797

Fig 1.

Fig 1.

Study design. The numbers of patients in the intention-to-treat population for L+T, T→L, L, and T were 1,155, 1,143, 1,168, and 1,147, respectively, for design 1; 833, 837, 827, and 840 for design 2; and 105, 111, 105, and 110 for design 2B. Design 1: neoadjuvant or adjuvant chemotherapy completed before randomization; anti-HER2 agents were given alone. Design 2: anthracycline component of adjuvant chemotherapy before randomization; taxanes were given concomitantly with anti-HER2 agents. Design 2B: nonanthracycline chemotherapy was given concomitantly with anti-HER2 agents. ALTTO, Adjuvant Lapatinib and/or Trastuzumab Treatment Optimization; HER2, human epidermal growth factor receptor 2; L, lapatinib; L+T, lapatinib plus trastuzumab; mFU, median follow-up; *R, time to randomization; T, trastuzumab; T→L, sequence of trastuzumab followed by lapatinib. †In Design 2B T was given for 18 weeks and L for 28 weeks.